抗菌药物降阶梯方案对重症下呼吸道感染患者肺部通气功能和血清炎性因子指标的影响

Effect of antibiotic de-escalation regimen on pulmonary ventilation function andserum inflammatory cytokines of patients with severe lower respiratory tract infections

  • 摘要: 目的 探究抗菌药物降阶梯方案对重症下呼吸道感染患者肺通气功能和血清炎性因子指标的影响。方法 收集2016年1月-2017年1月医院内科收治的重症下呼吸道感染患者68例,根据数字表法分为对照组和试验组,每组各34例,试验组予以美罗培南0.45 g+100 ml生理盐水静脉滴注,间隔6~12 h给药1次,连续治疗4 d后,根据患者痰细菌培养结果减少美罗培南用量0.5~1 g/d,或予以敏感抗菌药物治疗,共4~12 d; 对照组予以头孢曲松钠2 g+100 ml生理盐水静脉滴注,每日1次, 共治疗5~12 d,治疗结束后比较分析两组患者临床疗效、呼吸力学指标、血清炎性因子水平、肺功能指标水平及不良反应发生率。结果 试验组临床总有效率79.41%,高于对照组的55.88%(P<0.05); 治疗前两组患者呼吸力学指标、血清炎性因子水平、肺功能指标水平比较差异均无统计学意义,治疗后两组呼吸力学指标PIP、Raw以及WOB水平均降低,Cdyn水平均升高,且试验组患者PIP、Raw以及WOB水平降低幅度,Cdyn水平升高幅度均优于对照组(P<0.05); 治疗后两组患者血清BNP、CRP、IL-6、PCT水平均降低,试验组血清BNP、CRP、IL-6、PCT水平降低幅度优于对照组(P<0.05); 治疗后两组FEV1/FVC、FEV1/预计值水平均升高,与对照组相比,试验组FEV1/FVC、FEV1/预计值水平升高明显(P<0.05); 两组患者不良反应发生率比较,差异无统计学意义。结论 抗菌药物降阶梯方案对重症下呼吸道感染患者的临床疗效显著,改善血清炎性因子水平,改善肺部通气功能,药物安全性高,适宜临床应用推广。

     

    Abstract: OBJECTIVE To observe the effect of antibiotics de-escalation regimen on pulmonary ventilation function and serum inflammatory cytokines of patients with severe lower respiratory tract infections. METHODS A total of 68 patients with severe lower respiratory tract infections who were treated in internal medicine department from Jan 2016 to Jan 2017 were enrolled in the study and randomly divided into the control group and the experimental group, with 34 cases in each group.The experimental group was given intravenous drip of 0.45 g of meropenem plus 100 ml normal saline, once per 6-12 hours, after the continuous treatment for 4 days, the patients were treated with meropenem by reducing the dosage of 0.5-1 g/d or were treated with sensitive antibiotics for 4-12 days.The control group was given intravenous drip of 2g ceftriaxone sodium plus 100 ml normal saline, once daily, with the treatment for 5-12 days in total.The clinical efficacy, respiratory mechanics indexes, serum inflammatory cytokines, pulmonary function indexes and incidence of adverse reactions were observed and compared between the two groups of patients after the treatment. RESULTS The total effective rate of clinical treatment of the experimental group was 79.41%, significantly higher than 55.88% of the control group (P<0.05).There was no significant difference in the clinical efficacy, respiratory mechanics indexes, serum inflammatory cytokines or pulmonary function indexes between the two groups of patients before the treatment.The levels of respiratory mechanics indexes PIP, Raw and WOB of the two groups of patients were reduced after the treatment, while the Cdyn level was elevated, the amplitudes of reduced levels of PIP, Raw and WOB of the experimental group were significantly greater than those of the control group, and the amplitude of elevated Cdyn level of the experimental group was greater than that of the control group (P<0.05).The levels of serum BNP, CRP, IL-6 and PCT of the two groups of patients were reduced after the treatment, while the amplitudes of reduced serum BNP, CRP, IL-6 and PCT of the experimental group were greater than those of the control group (P<0.05).The FEV1/FVC and FEV1/expected value of the two groups of patients were significantly increased after the treatment, while the FEV1/FVC and FEV1/expected value of the experimental group were increased more remarkably than those of the control group (P<0.05).There was no significant difference in the incidence of adverse reactions between the two groups of patients. CONCLUSION The antibiotic de-escalation regimen may achieve remarkable clinical effect on the patients with severe lower respiratory tract infections, raise the levels of serum inflammatory cytokines and improve the pulmonary ventilation function, with the drug safety high, and it is worthy to be promoted in the hospital.

     

/

返回文章
返回